Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study.

WHAT IS KNOWN AND OBJECTIVE

Meropenem, a broad-spectrum carbapenem, is frequently used to treat severe bacterial infections in critically ill children. Recommendations for meropenem doses in adult infections are available; however, few studies have been published regarding the use of meropenem in children with sepsis, especially in those receiving continuous renal replacement therapy (CRRT) and extracorporeal membrane oxygenation (ECMO). We aimed to investigate the pharmacokinetic (PK) parameters of meropenem in children with sepsis receiving extracorporeal life support (ECLS).

METHODS

This was a prospective observational clinical study of children with sepsis receiving ECMO or CRRT in the paediatric intensive care unit (PICU) of a children's hospital. The enrolled children received 20 mg/kg meropenem infusion over 1 hour, every 8 hours, and were grouped into children receiving ECMO, children receiving CRRT and children receiving neither ECMO nor CRRT. Plasma meropenem concentrations were determined using a validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The key PK parameters were determined using the non-compartmental approach.

RESULTS AND DISCUSSION

Twenty-seven patients were finally enrolled. The eCLCR of the CRRT group was lower than that of the ECMO group. The values of elimination half-life (t ), area under the plasma concentration-time curve (AUC ), area under the plasma concentration-time curve from time zero to infinity (AUC ), and total clearance (CL) in the ECMO group were not different from those of the other groups (all p > 0.05). However, the AUC (p = 0.0137) and AUC (p = 0.0234) significantly decreased after filtration through a hemofiltration membrane in patients receiving CRRT.

WHAT IS NEW AND CONCLUSION

No significant alterations in the PK parameters of meropenem occurred in children with sepsis administered ECMO and/or CRRT. Further investigations including PK modelling could provide evidence for appropriate meropenem dosing regimens during ECLS administration.